Home Featured Page 44

Featured

Latest

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Diane Goldstein, Sarko Gergerian and Rick Doblin

Psychedelic Science 2025: A Convergence of Data, Discovery, and Integration

Zach Leary – Your Extraordinary Mind

Psychedelic Funding Update: Q1 2025

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Oakland Psychedelic Conference

Kayse Gehret – The Modern Guide: Microdosing, Facilitation & Community

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Diane Goldstein, Sarko Gergerian and Rick Doblin

Psychedelic Science 2025: A Convergence of Data, Discovery, and Integration

Zach Leary – Your Extraordinary Mind

Psychedelic Funding Update: Q1 2025

Hope, Hype, and Humility: Dr. Charles Raison Reflects on Psychedelics’, and...

High Hopes in the Mile High City: Inside Colorado’s First Licensed...

LP Giobbi – Dead House, Psychedelic Creativity, and Fem House Empowerment

Psychedelic Science 2025

Oakland Psychedelic Conference

Kayse Gehret – The Modern Guide: Microdosing, Facilitation & Community

EDITOR PICKS

220 Patients or 20,000? Clinics Split on Psychedelics’ First Year

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY